- Home
- NRO vs MOLN Comparison
NRO vs MOLN Comparison
Compare NRO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRO | MOLN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 147.5M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRO | MOLN |
|---|---|---|
| Price | $2.51 | $3.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.36 |
| AVG Volume (30 Days) | ★ 210.1K | 2.0K |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $450.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.49 | $3.52 |
| 52 Week High | $3.23 | $5.36 |
Technical Indicators
Market Signals| Indicator | NRO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 30.91 | 38.61 |
| Support Level | $2.49 | N/A |
| Resistance Level | $3.09 | $4.35 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 13.33 | 10.83 |
Price Performance
Historical ComparisonAbout NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.